Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 168

Sort by

Sort Order Select

Journal Articles

Factor VIII–antibody structure and membrane binding

Gary E. Gilbert

Blood (2021) 137 (21): 2866–2868.

https://doi.org/10.1182/blood.2021010947

Published: 2021

Journal Articles

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Ang Li, MD, Catlin Goodfriend, PharmD, John Sokol, PharmD, Rebecca Kruse-Jarres, MDMPH

Blood (2019) 134 (Supplement_1): 2178.

https://doi.org/10.1182/blood-2019-128083

Published: 2019

Journal Articles

Epitope Dependent Augmentation of the Immune Response in Hemophilia Α Mice Immunized with Factor VIII/Antibody Immune Complexes

Glaivy Batsuli, MD, Seema R Patel, PhD, Courtney Cox, MSc, Wallace H. Baldwin, John S. Lollar, MD, Shannon L. Meeks, MD

Blood (2019) 134 (Supplement_1): 2387.

https://doi.org/10.1182/blood-2019-127436

Published: 2019

Journal Articles

Immune Tolerance Induction (ITI) in Paediatric and Adult Patients with Haemophilia a (HA) and High-Titre (HT) Factor VIII (FVIII) Inhibitor - Real Life Data

Magdalena Katarzyna Letowska, Krystyna Zawilska, MD PhD, Anna Klukowska, MD PhD, Krzysztof Chojnowski, MD PhD, Joanna Zdziarska, MD PhD, Ewa Stefanska-Windyga, MD PhD, Jerzy Windyga

Blood (2019) 134 (Supplement_1): 4942.

https://doi.org/10.1182/blood-2019-122422

Published: 2019

Journal Articles

Higher Incidence of Neutralizing Anti-FVIII Antibodies (Inhibitors) in Black and Hispanic American Hemophilia A Patients Enrolled in the My Life, Our Future Programme

Kathleen P. Pratt, PhD

Blood (2019) 134 (Supplement_1): 901.

https://doi.org/10.1182/blood-2019-127412

Published: 2019

Journal Articles

A Novel Approach to Immune Tolerance Induction in Hemophilia Α with Factor VIII Inhibitor

Courtney D. Thornburg, MD, Jonathan M. Ducore, MD

Blood (2018) 132 (Supplement 1): 5042.

https://doi.org/10.1182/blood-2018-99-119800

Published: 2018

Journal Articles

A Novel Humanized Hemophilia-a Mouse Model to Facilitate Preclinical In Vivo Studies of Human Specific Fviiia-Mimetic Bispecific Antibodies

Wenjing Li, Jianxin Hu, PhD, Nina Leksa, PhD, Maria M Aleman, PhD, Robert Peters, PhD, Joe Salas, PhD, Arjan Van Der Flier, PhD

Blood (2018) 132 (Supplement 1): 2458.

https://doi.org/10.1182/blood-2018-99-119012

Published: 2018

Journal Articles

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Midori Shima, MD PhD, Keiji Nogami, MDPhD, Sayaka Nagami, BSc, Seitaro Yoshida, PhD, Koichiro Yoneyama, MSc, Akira Ishiguro, MD PhD, Takashi Suzuki, MD PhD, Masashi Taki, MD PhD

Blood (2018) 132 (Supplement 1): 1186.

https://doi.org/10.1182/blood-2018-99-115792

Published: 2018

Journal Articles

Genetics of Factor VIII Inhibitor Development in Hemophilia Patients: Novel Statistical Approaches in the PATH Study

Vincent P. Diego, PhD, Marcio A. Almeida, PhD, Bernadette W. Luu, BS, MT/CLS, Karin Haack, PhD, Meera B. Chitlur, MD, Afshin Ameri, MD, Long V. Dinh, PhD, Raja Rajalingam, PhD, Jerry S. Powell, MD, John Blangero, PhD, Laura Almasy, PhD, Shelley Cole, PhD, Tom E. Howard

Blood (2018) 132 (Supplement 1): 1199.

https://doi.org/10.1182/blood-2018-99-120021

Published: 2018

Journal Articles

The Un-BLyS-Ful State: Blocking Factor VIII Inhibitor Development with BLyS Depletion

Bhavya S Doshi, MD, Robert J. Davidson, BS, Valder R Arruda, MD PhD

Blood (2018) 132 (Supplement 1): 138.

https://doi.org/10.1182/blood-2018-99-114795

Published: 2018

Journal Articles

Understanding Disease Burden Among Persons with Hemophilia Α without Inhibitors

Wendy E Owens, MA, Anissa Cyhaniuk, Anisha Patel, Karina Raimundo, Elaine Chan, Richard H Ko

Blood (2018) 132 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2018-99-112121

Published: 2018

Journal Articles

Parallel Evaluation of Three Global Hemostatic Assays in Response to Factor VIII Inhibitors

Ping Chen, PhD, Jayesh Jani, Gang Zheng, MD PhD, Thomas S. Kickler, MD

Blood (2018) 132 (Supplement 1): 1172.

https://doi.org/10.1182/blood-2018-99-110722

Published: 2018

Journal Articles

Impact of Interleukin-6 and Interleukin-10 Gene Polymorphisms on Inhibitor Development in Patients with Moderate and Severe Hemophilia a

Hoda Hassab, MD, Marwa Hanafi, Ahmed Abdelmaksoud, Shimaa ElSayed

Blood (2018) 132 (Supplement 1): 5026.

https://doi.org/10.1182/blood-2018-99-117479

Published: 2018

Journal Articles

The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab

Glaivy M. Batsuli, MD, Karen L. Zimowski, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD

Blood (2018) 132 (Supplement 1): 634.

https://doi.org/10.1182/blood-2018-99-114249

Published: 2018

Journal Articles

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Mark T. Reding, MD, Jatin Rana, MD, Michael U. Callaghan, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD

Blood (2018) 132 (Supplement 1): 635.

https://doi.org/10.1182/blood-2018-99-115089

Published: 2018

Journal Articles

Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A

Patricia E. Zerra, Courtney Cox, W. Hunter Baldwin, Seema R. Patel, Connie M. Arthur, Pete Lollar, Shannon L. Meeks, Sean R. Stowell

Blood (2017) 130 (23): 2559–2568.

https://doi.org/10.1182/blood-2017-05-782912

Published: 2017

Includes: Supplemental data

Journal Articles

Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review

Heidi Chwan Ko, DO, Cristhiam Rojas Hernandez, MD, Thein Hlaing Oo, MD

Blood (2017) 130 (Supplement 1): 5639.

https://doi.org/10.1182/blood.V130.Suppl_1.5639.5639

Published: 2017

Journal Articles

HLA-DRB1-Peptide Binding Prediction and Risk of Inhibitor Development in Non-Severe Hemophilia a

Christine L Kempton, Amanda B. Payne, MPH

Blood (2017) 130 (Supplement 1): 177.

https://doi.org/10.1182/blood.V130.Suppl_1.177.177

Published: 2017

Journal Articles

Epitope Mapping of Inhibitor Patient Plasmas during Immune Tolerance Induction

Shannon L. Meeks, MD, Courtney Cox, MSc, W. Hunter Baldwin, BS

Blood (2017) 130 (Supplement 1): 2364.

https://doi.org/10.1182/blood.V130.Suppl_1.2364.2364

Published: 2017

Journal Articles

The Impact of Anti-Factor VIII A1 and A3 Domain Antibodies in the Immune Reponse to Factor VIII in Patients with Hemophilia a

Jasmine C Ito, Courtney Cox, MSc, W. Hunter Baldwin, BS, Christopher B Doering, PhD, Shannon L. Meeks, MD

Blood (2017) 130 (Supplement 1): 2373.

https://doi.org/10.1182/blood.V130.Suppl_1.2373.2373

Published: 2017

NARROW

Factor VIII–antibody structure and membrane binding

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Epitope Dependent Augmentation of the Immune Response in Hemophilia Α Mice Immunized with Factor VIII/Antibody Immune Complexes

Immune Tolerance Induction (ITI) in Paediatric and Adult Patients with Haemophilia a (HA) and High-Titre (HT) Factor VIII (FVIII) Inhibitor - Real Life Data

Higher Incidence of Neutralizing Anti-FVIII Antibodies (Inhibitors) in Black and Hispanic American Hemophilia A Patients Enrolled in the My Life, Our Future Programme

A Novel Approach to Immune Tolerance Induction in Hemophilia Α with Factor VIII Inhibitor

A Novel Humanized Hemophilia-a Mouse Model to Facilitate Preclinical In Vivo Studies of Human Specific Fviiia-Mimetic Bispecific Antibodies

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Genetics of Factor VIII Inhibitor Development in Hemophilia Patients: Novel Statistical Approaches in the PATH Study

The Un-BLyS-Ful State: Blocking Factor VIII Inhibitor Development with BLyS Depletion

Understanding Disease Burden Among Persons with Hemophilia Α without Inhibitors

Parallel Evaluation of Three Global Hemostatic Assays in Response to Factor VIII Inhibitors

Impact of Interleukin-6 and Interleukin-10 Gene Polymorphisms on Inhibitor Development in Patients with Moderate and Severe Hemophilia a

The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A

Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review

HLA-DRB1-Peptide Binding Prediction and Risk of Inhibitor Development in Non-Severe Hemophilia a

Epitope Mapping of Inhibitor Patient Plasmas during Immune Tolerance Induction

The Impact of Anti-Factor VIII A1 and A3 Domain Antibodies in the Immune Reponse to Factor VIII in Patients with Hemophilia a

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only